Collegium Pharmaceutical Says FDA Review Of Opioid Painkiller To Be Delayed The U.S. Food and Drug Administration has advised Collegium Pharmaceutical that it will not be able to complete its review of the company's opioid painkiller, Xtampza, by the deadline set for Oct.12, according to an update from Collegium. by Ted Ranosa
Healthy Living/Wellness FDA Panel Green Lights Approval of Collegium's Painkiller by Rina Marie Doctor